Novo Nordisk A/s

Argos Therapeutics, Inc.

Berit Olsen Krogh

Jens Breinholt

Ida Hilden

Jes Thorn Clausen

Helle Heibroch Petersen

Ole Hvilsted Olsen

Birgitte Friedrichsen

Mikael Kofod-Hansen

Soren Berg Padkjaer

Inger Lund Pedersen

Lars Anders Svensson

Brian Lauritzen

Lars Christian Petersen

Brit Binow Soerensen

Jan Fleckner

Brit Binow Sørensen

Cecilia Augustsson

Søren PADKJÆR

The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.

Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI&#x3b1;, even where the concentration of TFPI is abnormally elevated.

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.

Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Antibodies against tissue factor pathway inhibitor

The present invention provides humanized anti-human IFN-&#x3b1; monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.

Humanized antibodies against human interferon-alpha

Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor

Growing community of inventors

Roedovre, Denmark

Berit Olsen Krogh